Last reviewed · How we verify
NCT04674020: REFORM
Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment
Status unknown
Phase 4
Last updated 10 January 2022
What this trial tests
Phase 4 trial testing Erenumab in Migraine in 250 participants. Status unknown.
Timeline
22 October 2020
Primary endpoint
22 July 2025
22 July 2025
22 July 2025
Quick facts
| Lead sponsor | Danish Headache Center |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 250 |
| Start date | 22 October 2020 |
| Primary completion | 22 July 2025 |
| Estimated completion | 22 July 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Erenumab (ERENUMAB) — full drug profile →
Conditions studied
Sponsor
Danish Headache Center — full company profile →
Who can join
18 and older, any sex, with Migraine or Headache. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.
Karlsson WK, Ashina H, Cullum CK, Christensen RH, et al · · 2023 · cited 28× · PMID 37303034 · DOI 10.1186/s10194-023-01604-2 -
Differences in Cortical Morphology in People With and Without Migraine: A Registry for Migraine (REFORM) MRI Study.
Christensen RH, Ashina H, Al-Khazali HM, Zhang Y, et al · · 2024 · cited 21× · PMID 38630960 · DOI 10.1212/wnl.0000000000209305 -
Signs of Cortical Inflammation in Migraine Measured with Quantitative Magnetic Resonance Imaging: A Registry for Migraine (REFORM) Study.
Christensen RH, Ashina H, Al-Khazali HM, Ocampo-Pineda M, et al · · 2025 · cited 6× · PMID 39902552 · DOI 10.1002/ana.27197 -
Shared neural signatures of photophobia in migraine and post-traumatic headache: a task-based fMRI study.
Christensen RH, Al-Khazali HM, Melchior AG, Ashina M, et al · · 2025 · cited 3× · PMID 40610897 · DOI 10.1186/s10194-025-02088-y -
White matter tract differences in persistent post-traumatic headache, migraine, and healthy controls: a diffusion tensor imaging study.
Christensen RH, Al-Khazali HM, Gollion C, Chaudhry BA, et al · · 2025 · cited 1× · PMID 40615814 · DOI 10.1186/s10194-025-02084-2 -
Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study.
Karlsson WK, Christensen RH, Al-Khazali HM, Kallemose T, et al · · 2025 · PMID 40275185 · DOI 10.1186/s10194-025-02037-9
Verify or expand the search:
- PubMed search for NCT04674020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Erenumab
Trials testing the same drug.
- NCT05281770 — Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study · unknown
- NCT05334927 — China HeadAche DIsorders RegiStry · recruiting
- NCT05284019 — Real World Effectiveness of Eptinezumab in Participants With Migraine · Phase 4 · terminated
- NCT04970355 — Efficacy of Erenumab in Chronic Cluster Headache · Phase 2 · completed
- NCT04920331 — Study of Intravenous Erenumab in Patients With Status Migrainosus · Phase 1 · withdrawn
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other Danish Headache Center trials
Trials by the same sponsor.
- NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
- NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
- NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
- NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
- NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04674020 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
- Last refreshed: 10 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing